tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IBRX Stock Latest News

Citizens JMP healthcare analysts hold an analyst/industry conference call
The FlyCitizens JMP healthcare analysts hold an analyst/industry conference call
12d ago
JNJ
CGON
Promising Developments in ImmunityBio’s ANKTIVA for NSCLC: A Buy Rating Based on Lymphorestorative Potential and Broader Oncology Applications
PremiumRatings
Promising Developments in ImmunityBio’s ANKTIVA for NSCLC: A Buy Rating Based on Lymphorestorative Potential and Broader Oncology Applications
18d ago
IBRX
Buy Rating for ImmunityBio’s ANKTIVA: Promising Phase II Results and Potential Biomarker Identification
PremiumRatings
Buy Rating for ImmunityBio’s ANKTIVA: Promising Phase II Results and Potential Biomarker Identification
18d ago
IBRX
Citizens JMP healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
19d ago
JNJ
CGON
ImmunityBio study shows ANKTIVA reverses lymphopenia, extends survival
PremiumThe Fly
ImmunityBio study shows ANKTIVA reverses lymphopenia, extends survival
20d ago
IBRX
ImmunityBio’s Anktiva: A Promising Treatment for Long COVID?
PremiumCompany AnnouncementsImmunityBio’s Anktiva: A Promising Treatment for Long COVID?
21d ago
IBRX
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer?
Premium
Company Announcements
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer?
21d ago
IBRX
ImmunityBio announces early findings from Anktiva pilot study
Premium
The Fly
ImmunityBio announces early findings from Anktiva pilot study
1M ago
IBRX
ImmunityBio announces Anktiva trial
PremiumThe Fly
ImmunityBio announces Anktiva trial
1M ago
IBRX
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
PremiumCompany Announcements
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
1M ago
IBRX
ImmunityBio announces early findings from QUILT-106 trial
PremiumThe Fly
ImmunityBio announces early findings from QUILT-106 trial
2M ago
IBRX
ImmunityBio says VA hospital among first to administer ANKTIVA
PremiumThe Fly
ImmunityBio says VA hospital among first to administer ANKTIVA
2M ago
IBRX
ImmunityBio’s Shareholder Settlement Gains Preliminary Approval
PremiumCompany AnnouncementsImmunityBio’s Shareholder Settlement Gains Preliminary Approval
2M ago
8K
IBRX
ImmunityBio’s ANKTIVA: Expanding Oncology Potential and Market Growth Drive Buy Rating
Premium
Ratings
ImmunityBio’s ANKTIVA: Expanding Oncology Potential and Market Growth Drive Buy Rating
2M ago
IBRX
ImmunityBio Reports Revenue Growth Amidst Continued Investments
Premium
Company Announcements
ImmunityBio Reports Revenue Growth Amidst Continued Investments
2M ago
IBRX
ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update
PremiumCompany Announcements
ImmunityBio’s Innovative Approach to Glioblastoma: A Promising Clinical Update
2M ago
IBRX
ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment
PremiumCompany Announcements
ImmunityBio’s Innovative Immunotherapy Trial: A Potential Game-Changer in Cancer Treatment
2M ago
IBRX
ImmunityBio Announces $80 Million Securities Purchase
PremiumCompany Announcements
ImmunityBio Announces $80 Million Securities Purchase
2M ago
8K
IBRX
ImmunityBio reports Q2 revenue $26.4M, consensus $21.95M
PremiumThe Fly
ImmunityBio reports Q2 revenue $26.4M, consensus $21.95M
2M ago
IBRX
ImmunityBio announces $80M registered direct offering
PremiumThe FlyImmunityBio announces $80M registered direct offering
2M ago
IBRX
ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update
Premium
Company Announcements
ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update
3M ago
IBRX
ImmunityBio’s Novel Approach to Combat Lymphopenia: A Market Game-Changer?
Premium
Company Announcements
ImmunityBio’s Novel Approach to Combat Lymphopenia: A Market Game-Changer?
3M ago
IBRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >